More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.97B
EPS
-0.25
P/E ratio
--
Price to sales
2.74
Dividend yield
--
Beta
1.869336
Previous close
$15.41
Today's open
$15.60
Day's range
$14.97 - $15.62
52 week range
$7.07 - $20.15
show more
CEO
Tony Zook
Employees
2500
Headquarters
Fort Myers, FL
Exchange
NASDAQ Capital Market
Shares outstanding
129389465
Issue type
Common Stock
Healthcare
Medical Diagnostics & Screening
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Stephens Annual Investment Conference and the Piper Sandler 38th Annual Healthcare Conference.
Business Wire • Nov 6, 2026

What NeoGenomics (NEO) Said on Its Q3 Earnings Call
NeoGenomics NASDAQ: NEO reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and adjusted EBITDA guidance.
MarketBeat • Oct 29, 2026

NeoGenomics, Inc. (NEO) Q3 2026 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 29, 2026

NeoGenomics Reports Third Quarter 2026 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2026.
Business Wire • Oct 28, 2026

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
Zacks Investment Research • Oct 29, 2026

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.
Business Wire • Oct 15, 2026

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.
Business Wire • Oct 14, 2026

What's Going On With NeoGenomics Stock Tuesday?
Precision medicine and oncology diagnostics provider NeoGenomics Inc. (NASDAQ:NEO) on Monday announced an executive succession plan and preliminary third-quarter financial results for the period ended Sept. 30, 2026.
Benzinga • Oct 6, 2026

Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.
Investors Business Daily • Oct 6, 2026

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.
Business Wire • Oct 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell NeoGenomics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.